Abstracts tagged "Economics and gout"

Abstract Number: 2241 • 2016 ACR/ARHP Annual Meeting
Health Economics of Uncontrolled Gout in the United States: A Systematic Literature Review
Shaum Kabadi¹, Julie Myers², Christopher Bly², Ron Wielage² and Robert Morlock³, ¹AstraZeneca, Gaithersburg, MD, ²Medical Decision Modeling Inc., Indianapolis, IN, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout is a crystal deposition disease and the most prevalent inflammatory arthritis in the United States (US). Maintaining gout control has been associated with…
Abstract Number: 1155 • 2014 ACR/ARHP Annual Meeting
Economic Impact of Frequent Gout Flares in a Managed Care Setting
Robert Jackson¹, Aki Shiozawa², Erin Buysman³, Aylin Altan³, Stephanie Korrer³ and Hyon K. Choi⁴, ¹Global Medical Office, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ²One Takeda Parkway, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ³Health Economics and Outcomes Research, Optum, Eden Prairie, MN, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose Gout is the most common inflammatory arthritis in the US. For most patients, excruciatingly painful gout attacks (“flares”) are the major clinical burden of…
Abstract Number: 211 • 2013 ACR/ARHP Annual Meeting
The Economic Burden Of Gout: A Systematic Review Of Direct and Indirect Costs
Sharan Rai¹, Aliya Haji², Lindsay C Burns³ and Hyon Choi^4,5, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The prevalence of gout, an excruciating and disabling joint disease, has been increasing in recent decades such that it now constitutes the most…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.